Digital health: the new AI‑driven tele‑monitoring system for chronic patients
Health‑Watch, launched by the Swiss Federal Office of Public Health and the Swiss Health Federation, utilises certified wearables, cloud‑based AI and blockchain to monitor chronic patients round‑the‑clock, cutting hospital admissions by 27 % and saving CHF 1 850 per patient each year.
On 8 May 2026 the Swiss Federal Office of Public Health (FOPH), in partnership with the Swiss Health Federation (SHF), rolled out Health‑Watch, Switzerland’s inaugural AI‑enabled, continuous‑monitoring platform for individuals living with chronic illnesses.
Operation principle
Each participant is supplied with a CE‑marked wearable capable of measuring heart‑rate, blood pressure, oxygen saturation and, for diabetic users, interstitial glucose. Raw data are encrypted using AES‑256 and transmitted via 5G/LTE to a domestic gateway, which forwards the stream to a federated cloud platform housed in ISO 27001‑certified Swiss data‑centres.
Within the cloud, a machine‑learning engine merges CNN (Convolutional Neural Networks) and LSTM (Long‑Short‑Term‑Memory) architectures to process the information in real‑time. The model – trained on over 12 million anonymised clinical records from university hospitals in Zurich, Lausanne and Basel – attains 97 % sensitivity and 95 % specificity for detecting ventricular arrhythmias, severe hypoglycaemia and hypoxic events.
When a physiological parameter breaches a pre‑set limit, the AI generates an alert (low, medium, high) that is dispatched simultaneously to the patient’s primary‑care dashboard and to the 24/7 Health‑Watch monitoring centre. Operators, aided by Decision‑Support Systems (DSS), may:
commence a tele‑consultation video within five minutes;
summon an emergency response unit with exact GPS coordinates;
amend medication (e.g., insulin dosage) directly via the portal, following electronic physician authorisation.
All actions are recorded on a private blockchain (Hyperledger Fabric), ensuring immutability and a comprehensive audit trail – a prerequisite under Swiss data‑protection legislation (LPD) and the EU General Data Protection Regulation (GDPR).
Pilot trial outcomes
A controlled pilot at the University Hospital of Zurich’s Internal Medicine Department enrolled 5 000 patients with chronic heart failure, COPD and type‑2 diabetes. The results (SHF White Paper, 8 May 2026) were:
Metric | Outcome |
|---|---|
Hospital admission reduction for arrhythmias | 27 % |
Decline in hypoglycaemia‑related admissions | 31 % |
Patient Net Promoter Score (NPS) | +12 points |
Median response time of monitoring team | 4 minutes |
Annual per‑patient cost saving | CHF 1 850 |
Early detection facilitated pre‑emptive actions that averted intensive‑care stays in numerous instances. Continuous monitoring also lifted treatment adherence; diabetic participants displayed an average HbA1c reduction of 0.6 % versus the control cohort.
Security, privacy and governance
Beyond end‑to‑end encryption, the platform employs Zero‑Knowledge Proofs to confirm data integrity without revealing raw values to third parties. Access is safeguarded with multi‑factor authentication (MFA) that combines hardware tokens and facial biometrics, fully complying with FINMA’s fintech‑health security guidelines.
An independent governance board, comprising bio‑ethicists, patient‑advocate representatives and cantonal health authorities, oversees model updates and audits for algorithmic bias, guaranteeing equitable performance across age groups, linguistic minorities and other vulnerable populations.
Future outlook and scaling
Health‑Watch aims to cover 15 000 chronic patients by 2028, widening its scope to neurological disorders (e.g., multiple sclerosis) and oncology (chemotherapy toxicity monitoring). A public‑private partnership with Swiss insurers will embed the service within “home‑care” health‑insurance packages, allowing reimbursable tele‑monitoring as a preventive benefit.
At the European level, the European Medicines Agency (EMA) has shown interest in adopting the platform for post‑marketing pharmacovigilance, potentially establishing a cross‑border standard for remote‑patient data.
In summary, the AI‑driven tele‑monitoring system marks a decisive advance in digital health, delivering tangible clinical improvements, cost efficiencies and rigorous privacy compliance. Should the current trajectory persist, Switzerland is set to become the global benchmark for AI‑enhanced, continuous chronic‑care management.